Viridian Therapeutics, Inc.
HealthcareNASDAQ:VRDN · NASDAQ Capital Market
+$0.21 today
Vol 1.24M · Avg 2.84M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-47.4%
avg 279.3%
ROIC
-43.8%
avg -266.7%
ROA
-38.1%
avg -81.8%
Analysis
ROA is currently the strongest return metric at -38.1% versus its period average of -81.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Stephen F. Mahoney | Chief Executive Officer, President & Director | $1.34M | — | 55 | $55,071.00 | 0.06% |
Thomas W. Beetham | Chief Operating Officer | $972,976.00 | — | 56 | $13,271.00 | 0.01% |
Radhika Tripuraneni | Chief Medical Officer | $840,686.00 | — | 46 | $95,800.00 | 0.11% |
Jennifer Tousignant | Chief Legal Officer & Corporate Secretary | $819,951.00 | — | 53 | $3,494.00 | <0.01% |
Seth Harmon | Chief Financial Officer | $785,651.00 | — | 45 | $7,850.00 | <0.01% |
Melissa Manno | Chief Human Resources Officer | — | — | — | — | — |
Eric N. Olson | Co-Founder & Chairman of Scientific Advisory Board | — | — | — | — | — |
Marvin H. Caruthers | Co-Founder & Scientific Advisory Board Member | — | — | 86 | — | — |
Michael R. Bristow | Co-Founder & Member of the Scientific Advisory Board | — | — | 81 | — | — |
Anthony Casciano | Chief Commercial Officer | — | — | 49 | — | — |
Vahe Bedian | Co-Founder & Scientific Advisor | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$30.00M
Sells
1
$70,795.52
Net Sentiment
+$29.93M
Net buying
Most Active
Fairmount Funds Management LLC
2 transactions
Analysis
Insiders reported 2 buys worth $30.00M and 1 sells worth $70,795.52 over the last 12 months. That adds up to net buying of $29.93M. Fairmount Funds Management LLC was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | -8.2% | +51.6% (14yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Recent growth has been strongest in Revenue at -8.2% over three years. Forward estimates point to Revenue at +51.6% (14yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
ImmunityBio, Inc.
NASDAQ:IBRX
$7.44B
Cogent Biosciences, Inc.
NASDAQ:COGT
$5.66B
Edgewise Therapeutics, Inc.
NASDAQ:EWTX
$3.75B
Structure Therapeutics Inc.
NASDAQ:GPCR
$2.47B
Vera Therapeutics, Inc.
NASDAQ:VERA
$2.46B
Arcus Biosciences, Inc.
NYSE:RCUS
$2.40B
Celldex Therapeutics, Inc.
NASDAQ:CLDX
$2.08B
Ocular Therapeutix, Inc.
NASDAQ:OCUL
$1.96B
Galapagos N.V.
GLPG
$1.84B
uniQure N.V.
NASDAQ:QURE
$1.74B
Who manages VRDN?
Viridian Therapeutics, Inc. (VRDN) lists 11 active executives. The top listed executive is Jennifer Tousignant, Chief Legal Officer & Corporate Secretary.
Are VRDN insiders buying or selling?
Recent insider activity shows net buying of $260.02M.
Explore More
Continue the stock analysis
Jump to another research area for this company.